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ABSTRACT
Chemotherapy sensitivity has been identified as an important prognostic factor in reduced-intensity allogeneic
stem cell transplantation (RIST) for non-Hodgkin lymphoma (NHL). However, the effect of uniform salvage
chemotherapy before RIST has not been studied prospectively. We examined whether the response to
prospectively administered uniform salvage therapy (etoposide, prednisone, vincristine, cyclophosphamide,
doxorubicin, and fludarabine) influenced the subsequent outcome of RIST in 28 patients with relapsed or
refractory NHL. After RIST, overall survival (OS) at 36 months is 49%, whereas event-free survival (EFS) is
32%. In Cox model analyses, the response to chemotherapy was the best predictor of OS (P  .0006) and EFS
(P  .0006) after RIST. Differentiating stable disease from progressive disease after salvage chemotherapy
strengthened the association with survival. Among chemotherapy-sensitive patients, the median OS and EFS
have not been reached. In patients with stable disease, OS and EFS at 24 months are 50% and 25%,
respectively. In contrast, only 1 patient with progressive disease during salvage therapy survived longer than 12
months. These prospective data confirm the favorable prognosis for chemotherapy-sensitive NHL after RIST
and suggest that chemotherapy resistance is not an absolute contraindication to RIST for NHL patients with
stable disease during salvage therapy.
© 2005 American Society for Blood and Marrow Transplantation
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[NTRODUCTION
Curative options are limited for patients with re-
ractory B-cell non-Hodgkin lymphomas (NHL).
onventional-dose chemotherapy seldom achieves
urable remissions for indolent or chemotherapy-re-
istant aggressive NHL [1-3], and autologous hema-
opoietic stem cell transplantation (HSCT) often fails
o improve survival in these settings [4,5]. For such
atients, allogeneic HSCT has potential efﬁcacy that
s attributed at least in part to immune-mediated
raft-versus-lymphoma (GVL) effects [6,7]. However, y
B&MToxicity and disease progression are signiﬁcant causes
f treatment failure after myeloablative allogeneic
SCT for NHL, and retrospective analyses have
dentiﬁed the response to salvage chemotherapy as an
mportant predictor of both disease-free and overall
urvival (OS) in this setting [6,8,9].
Reduced-intensity conditioning regimens de-
rease the acute toxicities associated with transplanta-
ion conditioning but increase the reliance on GVL
ffects for the curative potential of allogeneic HSCT
10,11]. It is therefore unsurprising that recent anal-
ses have found reduced-intensity stem cell transplan-
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5ation (RIST), like myeloablative allografting, to be of
imited beneﬁt for chemotherapy-resistant lymphoma
12]. However, these studies determined chemosensi-
ivity on the basis of varied salvage regimens admin-
stered at different centers before RIST and did not
istinguish stable disease from progression when iden-
ifying patients as refractory to salvage chemotherapy.
uch distinctions may be particularly relevant in the
ontext of reduced-intensity conditioning. These ob-
ervations and the relative paucity of published data
n RIST for NHL make it difﬁcult to fully interpret
he role of chemosensitivity in patient selection for
his procedure.
To help address these issues, we prospectively
dministered dose-adjusted etoposide, prednisone,
incristine, cyclophosphamide, doxorubicin, and ﬂu-
arabine (EPOCH-F) as uniform salvage chemother-
py for refractory or relapsed NHL before RIST. On
he basis of the demonstrated efﬁcacy of EPOCH
alvage therapy in relapsed NHL [13], the EPOCH-F
egimen was developed both to control disease and to
rovide immune suppression before RIST in an effort
o augment GVL activity through rapid and complete
onor engraftment without myeloablation [14,15].
e hypothesized that this strategy would partially
vercome the adverse effect of chemotherapy resis-
ance on long-term outcome after RIST. To evaluate
his in a preliminary manner, we studied the associa-
ion between response to EPOCH-F and survival after
IST, speciﬁcally differentiating chemotherapy-resis-
ant patients with stable disease from those with pro-
ressive disease (PD).
ATIENTS AND METHODS
ligibility Criteria
Eligibility required NHL that was primary refrac-
ory or had progressed after second-line therapy or
utologous HSCT. Diagnoses were conﬁrmed by the
ational Cancer Institute Laboratory of Pathology by
sing the revised European-American lymphoma clas-
iﬁcation [16] or the World Health Organization clas-
iﬁcation [17]. Additional criteria included an age of
6 to 75 years, a Karnofsky performance status70%,
nd adequate hepatic, renal, pulmonary, and cardiac
unction. All patients had an acceptable 6/6 (n  28)
r 5/6 (n  1) HLA-matched sibling donor. The
rotocol, CC 99-C-0143, was approved by the Na-
ional Cancer Institute Institutional Review Board
18]. Each patient and donor provided written in-
ormed consent before study entry.
alvage Chemotherapy
The salvage regimen and RIST procedure have
reviously been described [19]. Before allogeneic
SCT, all patients received salvage chemotherapy a
94ith EPOCH-F, which consisted of a continuous in-
ravenous (IV) infusion of etoposide (50 mg/m2/d),
oxorubicin (10 mg/m2/d), and vincristine (0.5 mg/
2/d) on days 1 to 3; a cyclophosphamide (600 mg/
2) IV bolus infusion on day 4; prednisone (60 mg/
2/d) orally on days 1 to 4; and a ﬂudarabine (25
g/m2/d) IV bolus infusion on days 1 to 3. Filgrastim
10 g/kg/d) was given subcutaneously from day 5 of
ach cycle until patients attained an absolute neutro-
hil count of 1000 cells per microliter for 2 consec-
tive days. EPOCH-F was administered every 21 days
o achieve a target peripheral blood CD4 level 50
ells per microliter before the initiation of transplan-
ation conditioning. Every patient received at least 1
ycle of EPOCH-F. Patients with PD or prohibitive
oxicity after 1 or 2 cycles proceeded directly to RIST
egardless of the CD4 count. Otherwise, patients pro-
eeded to RIST after 3 cycles of EPOCH-F, regard-
ess of the CD4 count or disease response.
eripheral Blood Stem Cell Mobilization,
ollection, and Transplantation
Hematopoietic progenitor cells were mobilized
ith ﬁlgrastim at 10 g/kg/d, and apheresis was per-
ormed on days 5 and 6 of ﬁlgrastim administration.
he reduced-intensity conditioning regimen con-
isted of ﬂudarabine (30 mg/m2/d) and cyclophosph-
mide (1200 mg/m2/d) administered concomitantly
V on days 6, 5, 4, and 3 before transplanta-
ion. Mesna (1200 mg/m2/d) was given on days 6
hrough 3 by continuous IV infusion. Cryopre-
erved cells were thawed and infused on day 0. Fil-
rastim was administered daily at 10 g/kg from the
ay of allogeneic HSCT until the absolute neutrophil
ount was5000 cells per microliter for 3 consecutive
ays. Patients received cyclosporine beginning on day
1 before transplantation and continuing until 100
ays after allogeneic HSCT and then were tapered to
iscontinuation by day 180 in the absence of graft-
ersus-host disease (GVHD). Throughout induction
hemotherapy and posttransplantation immunosup-
ression, infection prophylaxis consisted of tri-
ethoprim/sulfamethoxazole, acyclovir, and ﬂucon-
zole. To avoid potential interactions with vincristine,
uconazole was stopped during EPOCH-F adminis-
ration.
esponse Evaluation
All patients underwent computerized axial tomog-
aphy (CT) of the chest, abdomen, and pelvis and a
one marrow examination immediately before study
ntry. CT was repeated after each cycle of EPOCH-F;
t posttransplantation day 28 and day 100, 6
onths, 9 months, and 12 months; and annually
hereafter. Bone marrow examination was repeated in
ll patients at day 28 and day 100. If bone marrow
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Bnvolvement was present at baseline, repeat examina-
ions were also performed after the last cycle of
POCH-F and at 6 and 12 months after RIST. CT
nd bone marrow studies were obtained at other times
f clinically warranted.
The following deﬁnitions were used for responses
o induction chemotherapy during the conduct of the
rial. Complete response (CR) was deﬁned according
o standard criteria[20] as regression of all lymph
odes to a normal size (1.5 cm), resolution of soft
issue masses or palpable organomegaly due to lym-
homa, and clearance of bone marrow inﬁltration (if
reviously present). Also consistent with standard def-
nitions, partial response (PR) required a minimum
0% reduction in the sum of the products of the
iameter of reference lesions without enlargement of
ther lesions, including the liver and spleen. PD was
eﬁned by the appearance of any new lesion or any
ncrease in the sum of the products of the diameter of
n existing lesion. Patients who did not meet criteria
or PD, PR, or CR by these deﬁnitions were catego-
ized as having stable disease.
tatistical Analysis
Survival and time to progression were calculated
rom the date of transplantation until death, progres-
ion, or last follow-up, as appropriate, through Janu-
ry 2004. Event-free survival (EFS) considered cases
f disease progression or death without progression as
reatment failures. Only patients who underwent
IST were evaluable for survival, EFS, or acute
VHD. Patients who survived for less than 100 days
fter transplantation were not evaluable for chronic
VHD. The probability of survival or EFS was cal-
ulated by using the Kaplan-Meier method [21], and
he signiﬁcance of the difference between pairs of
aplan-Meier curves was calculated with the Mantel-
aenszel procedure [22]. The Cox proportional haz-
rds model was used to identify which factors were
ointly signiﬁcant in the association with survival or
FS [23]. The factors considered for inclusion in
nivariate and Cox analyses were age, stage, number
f extranodal sites, serum lactate dehydrogenase, In-
ernational Prognostic Index score at study entry, his-
ologic aggressiveness, duration of disease, previous
egimens (number and speciﬁc agents), previous au-
ologous HSCT, response to the most recent therapy
efore enrollment, and response to EPOCH-F. For
omparison, the response to EPOCH-F was analyzed
y using both the trial deﬁnitions and standard crite-
ia.
In the univariate analyses, results for the Interna-
ional Prognostic Index score were evaluated at each
ossible dichotomy and pooled into groups after ini-
ial examination of results. Because the International
rognostic Index score was reduced to 2 groups with w
B&MTifferent outcomes in the subsequent analysis and be-
ause 3 such potential formations exist, the adjusted P
alue is reported as the unadjusted P value multiplied
y 3. Factors associated with an unadjusted P value
.20 were subsequently evaluated in a Cox model.
he resulting model parameters were converted to
elative risks with associated 95% conﬁdence intervals
CIs) [24]. The relationship between the response to
he most recent prior therapy and the response to
POCH-F on this study (CR/PR versus stable disease
ersus PD) was evaluated by using an exact Cochran-
rmitage test [25]. All reported P values are 2 tailed.
ESULTS
atient Characteristics
Twenty-nine patients were enrolled between July
999 and September 2002. Baseline characteristics at
tudy entry (Table 1) included a median age of 48
ears (range, 31-69 years) and a median of 3 prior
reatment regimens (range, 1-5). Most patients had
rimary (n  13) or transformed (n  4) diffuse large
-cell NHL. Six patients had received high-dose che-
otherapy and autologous HSCT. On the basis of the
esponse to the most recent prior therapy, 16 patients
able 1. Patient Characteristics
Variable Data
edian age at study entry, y (range) 48 (31–69)
ex
Male 16 (55%)
Female 13 (45%)
istology (n)
Follicular lymphoma (large-cell transformation,
n  4) 12
Diffuse large B-cell lymphoma 13
Mantle cell lymphoma 4
edian time from diagnosis to study entry, mo
(range) 20 (5–149)
rior treatment
Median number of prior regimens (range) 3 (1–5)
Prior anthracycline-containing regimen 27 (93%)
Prior fludarabine 4 (14%)
Prior rituximab 18 (62%)
Prior autologous HSCT 6(21%)
isease status at study entry
Sensitive 16 (55%)
Resistant 11 (38%)
Untested 2 (7%)
isease stage at study entry
Remission 1 (3%)
I 1 (3%)
II 4 (14%)
III 6 (21%)
IV 17 (59%)
NS involvement 5 (17%)
one marrow involvement 12 (41%)
ther extranodal involvement 20 (69%)
SCT indicates hematopoietic stem cell transplantation; CNS,
central nervous system.ere deemed chemosensitive and 11 were deemed
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5hemorefractory at study entry. Two patients were in
ntested relapse.
nduction Chemotherapy
Patients received a median of 2 cycles (range, 1-3)
f EPOCH-F (Table 2). In 9 patients, EPOCH-F was
iscontinued after 1 or 2 cycles, despite the persis-
ence of more than 50 CD4 cells per microliter,
ecause of disease progression. Eight of these patients
roceeded to transplantation, and 1 withdrew from
he study before RIST and died of progressive NHL.
verall, treatment with EPOCH-F resulted in CRs in
patients, PRs in 8, stable disease in 8, and PD in 10.
here was no association between the response to
rior therapy before study entry and the response to
POCH-F (exact Cochran-Armitage test; P  .26).
ematopoietic Recovery and Engraftment
Twenty-eight patients proceeded to transplanta-
ion, and 27 were evaluable for hematopoietic recov-
ry and engraftment. Patients received a median 7.83
106 CD34 cells per kilogram (range, 3.46-17.8 
06) and 3.36  108 CD3 cells per kilogram (range,
.67-9.38  108). The median times to neutrophil
ecovery (500  109/L) and platelet recovery (20
109/L without transfusion) were 9 and 10 days,
espectively. Donor engraftment was rapid, with a
edian total mononuclear cell donor chimerism of
9% at day 14 after transplantation. Donor lym-
hoid chimerism was complete in most patients (me-
ian of 99% at day 14) and was sustained through
ay 100 in all patients examined. No patient expe-
ienced graft rejection or failure.
ransplantation Outcome
The median potential follow-up after RIST is 33.4
onths. The median OS is 18.1 months, with an
ctuarial OS of 49% at 36 months. The median EFS
s 5.9 months, with an actuarial EFS of 32% at 36
onths. Causes of death after RIST included PD (n
), GVHD with (n  2) or without (n  4) infection,
nd sudden cardiac death (n  1). Grades II to IV
cute GVHD occurred in 19 patients (68%). In 4
able 2. EPOCH-F Induction Chemotherapy
No. Cycles
Administered
Response to EPOCH-F Total
PatientsCR PR SD PD
1 5 4 9 (31%)
2 1 1 5 7 (24%)
3 3 7 2 1 13 (45%)
otal
patients 3 (10%) 8 (28%) 8 (28%) 10 (34%)
R indicates complete response; PR, partial response; SD, stable
disease; PD, progressive disease.atients, acute GVHD occurred after cyclosporine
96as changed to another immunosuppressant because
f toxicity (n 3) or was discontinued for PD (n 1).
ifteen (63%) of 24 evaluable patients developed
hronic GVHD. Thirteen patients who developed
cute GVHD and 7 who developed chronic GVHD
ied.
Disease progression after RIST occurred in 11
atients, among whom 7 experienced acute GVHD
nd 4 developed chronic GVHD; 7 of these 11 pa-
ients subsequently died. Four patients with PD after
IST received donor lymphocyte infusions (DLI)
ith (n 3) or without salvage chemotherapy. One of
hese patients is alive with persistent disease, and 3
urvive in remission at a median of 24 months after
IST and 18 months after DLI. Neither acute nor
hronic GVHD occurred in these 3 patients.
Univariate analysis identiﬁed patient age, Interna-
ional Prognostic Index score, and response to
POCH-F as factors potentially associated with OS
Table 3). Cox model analysis of these factors deter-
ined that the response to salvage chemotherapy was
he best predictor for OS. This association was stron-
est when salvage response was categorized into 3
roups: CR/PR, stable disease, or PD (hazard ratio,
.31; 95% CI, 1.85-10.00; P  .0006; Figure 1). At 24
onths after RIST, the estimated OS for patients with
hemosensitive or stable lymphoma during EP-
CH-F was 80% (95% CI, 48%-94%) and 50%
95% CI, 22%-79%), respectively. The estimated OS
or patients with PD during EPOCH-F was 11% at 12
onths and could not be estimated at 24 months.
able 3. Results of Univariate Analysis
Variable
P Value
OS EFS
ge (up to 60 vs. >60 y) .055 .13
tage (NED/I/II vs. III/IV) .30 .63
umber of extranodal sites (0–1 vs. >2) .85 .55
erum LDH (<226 vs. >226) .22 .13
PI score (0/1 vs. >2) .11* .50*
istology (aggressive vs. indolent) .45 .12
uration of disease (0–24 vs. >24 mo) .72 .23
umber of previous regimens (0–2 vs. >3) .96 .74
rior autologous HSCT .96 .094
rior fludarabine .74 .71
rior anthracycline .40 .28
rior rituximab .75 .87
esponse to most recent therapy (CR/PR
vs. SD/PD) .47 .44
esponse to EPOCH-F
CR/PR vs. SD/PD .0038 .0009
CR/PR vs. SD vs. PD .0001 .0007
ED indicates no evidence of disease; IPI, International Prognostic
Index; HSCT, hematopoietic stem cell transplantation; CR,
complete response; PR, partial response; SD, stable disease; PD,
progressive disease; LDH, lactate dehydrogenase; OS, overall
survival; EFS, event-free survival.
P value adjusted to account for pooling of data after initial exam-
ination.
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Bnly 1 patient with PD during induction chemother-
py remained alive at the time of this analysis.
Potential factors associated with EFS in the uni-
ariate analysis included age, serum lactate dehydro-
enase, histology, prior autologous HSCT, and re-
ponse to EPOCH-F (Table 3). Cox model analysis of
hese factors determined that the response to
POCH-F, categorized into 3 groups, was the best
redictor for EFS (hazard ratio, 3.06; 95% CI, 1.62-
.73; P  .0006; Figure 2). No other variables re-
ained signiﬁcant in the Cox model when the re-
ponse to EPOCH-F was included. The estimated
FS at 24 months was 70% (95% CI, 39%-90%) for
atients with chemosensitive lymphoma versus 25%
95% CI, 7%-59%) for patients with stable disease.
he estimated progression-free survival for patients
ith PD during EPOCH-F was 11% at 12 months
nd could not be estimated at 24 months.
Compared with patients with PD, those with sta-
le disease before RIST responded more frequently to
nterventions for disease progression after RIST (Ta-
le 4). Speciﬁcally, only 4 stable disease patients died
rom treatment failure after RIST, and 2 others are in
ontinuous CR after salvage chemotherapy and DLI.
n contrast, there were no survivors among patients
ith PD before RIST whose lymphoma subsequently
rogressed after RIST. Thus, although EFS was sim-
lar for patients whose salvage response was stable
isease compared with PD, those with stable disease
ad a better OS.
ISCUSSION
Response to chemotherapy has been identiﬁed in
etrospective analyses as an important clinical prog-
ostic factor for outcomes after RIST for NHL [12].
ur study conﬁrms and strengthens this observation
igure 1. Overall survival after RIST according to response to
POCH-F. Responses to EPOCH-F were categorized as complete
r partial response (CR/PR), stable disease (SD), or progressive
isease (PD).rospectively by using a single salvage chemotherapy e
B&MTegimen. EPOCH-F was administered to achieve both
isease control and targeted host immune depletion
efore RIST [26]. This design permitted us to evalu-
te the relationship between salvage response and
IST outcome more uniformly than was possible in
rior analyses. By restaging after each cycle of salvage
herapy, we observed that a trend toward disease pro-
ression after even 1 cycle seemed sufﬁcient to predict
high risk of treatment failure after RIST. In contrast,
or patients with chemosensitive lymphoma or mini-
ally responding stable disease, it may be advanta-
eous to continue salvage chemotherapy for further
ytoreduction before RIST.
This analysis suggests additional insights into the
otential susceptibility of chemotherapy-resistant
ymphomas to GVL effects after RIST. We observed,
s might be hypothesized, that OS after RIST was
ore likely for patients with stable disease during
alvage therapy than for patients with PD, despite
imilar EFS for these groups. The improved OS for
atients with stable disease occurred principally be-
ause some who experienced disease progression after
IST still achieved durable remission with DLI. This
uggests that stable disease patients may be more sen-
itive to GVL effects than those with PD during
alvage chemotherapy. This distinction was not evi-
ent from prior studies and is potentially important,
ecause some authors have questioned the beneﬁt of
IST for patients without chemosensitive lymphoma
12,27], as deﬁned by achieving a PR or CR with
alvage therapy. In this exploratory analysis, classify-
ng the response to salvage chemotherapy for NHL as
ensitive (CR/PR), stable, or progressive predicted
urvival after RIST more accurately than categorizing
he salvage response as a dichotomous variable
CR/PR versus stable disease/PD). This is one of the
argest single-institution series of RIST for NHL that
as been published to date; nonetheless, these results
hould be interpreted with caution, considering the
igure 2. Event-free survival after RIST. SD indicates stable dis-
ase.
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5ize of each salvage response group. Conﬁrmation of
hese ﬁndings in larger retrospective and prospective
tudies is highly desirable.
We performed this analysis on a relatively small
ut consistently treated patient population. Although
atients with 3 histologic types of NHL were in-
luded, this heterogeneity is arguably irrelevant, given
he uniformly poor prognosis of refractory NHL re-
ardless of histology [8,12]. Consistent with this as-
ertion, histology was not associated with survival af-
er RIST in the univariate analysis. The strength of
he association between salvage response and RIST
utcome also argues against histology’s being an im-
ortant predictor of outcome in this study.
A signiﬁcant number of nonrelapse deaths oc-
urred in this study. Outcomes tended to be better in
atients who received the most salvage chemotherapy
ycles, most of whom had chemosensitive disease, but
e cannot exclude a possible contribution of the sal-
age regimen to treatment-related mortality after
IST in some patients. In particular, morbidity from
VHD was relatively high compared with other re-
orted studies of RIST. We used single-agent cyclo-
porine for GVHD prophylaxis, and the incidence of
cute GVHD among these patients was similar to that
bserved with cyclosporine monotherapy after my-
loablative allogeneic HSCT [28]. Our subsequent
esearch efforts in RIST have focused on reducing
orbidity from GVHD while preserving the engraft-
ent results seen in this study.
Disappointingly, most patients with PD during
alvage therapy died after RIST; treatment failures
esulted equally from relapse and nonrelapse causes.
ontrary to our hopes, rapid and complete donor
ngraftment did not seem to enhance GVL effects
ufﬁciently to overcome disease resistance in this
roup, and such rapid engraftment likely contributed
o the GVHD-related toxicity we observed. The poor
urvival after RIST for these patients remains a con-
ern and demonstrates that further work is needed to
mprove outcomes for this high-risk population.
Little is known about the biological mechanisms
hrough which chemosensitivity is related to immune-
ediated GVL effects, but various factors may be
elevant. Murine models indicate that the Fas ligand
able 4. Outcomes of Patients after RIST, According to EPOCH-F Re
EPOCH-F Response EFS NRM D
R/PR (n  11) 8 1
D (n  8) 1 2
D (n  9) 1 4
IST indicates, reduced-intensity stem cell transplantation; NRM, n
partial response; SD, stable disease.
Denotes patients who achieved remission after donor lymphocytend perforin cytolytic pathways both contribute to
98VL activity [29]. Other experimental data suggest
hat tumor masses may inhibit speciﬁc T-cell re-
ponses [30]; thus, lymphomas that can be cytore-
uced to a minimal disease state before transplanta-
ion might be more susceptible to GVL effects.
hemotherapy-induced tumor cell lysis may itself
romote GVL activity via increased antigen presenta-
ion to allogeneic T cells. In contrast, the growth
inetics of rapidly progressive lymphoma may outstrip
he pace at which GVL-mediated tumor cell death
ccurs. Resistance to cytotoxic agents and to GVL
ffects may be mediated through common pathways,
uch as altered susceptibility to apoptotic signals. Fur-
her characterization of these relationships may pro-
ide better prognostic tools to select NHL patients for
llogeneic HSCT.
This analysis conﬁrms, in a uniformly treated
roup of patients with refractory or relapsed NHL,
hat chemotherapy-sensitive disease has a favorable
rognosis after RIST. Additionally, we observed a
tronger association between salvage response and OS
y separating chemotherapy-refractory NHL patients
nto 2 groups (stable disease versus PD) than if they
ere combined. In conclusion, failure to respond to
hemotherapy does not necessarily preclude a beneﬁt
rom RIST and should not be used independently of
ther factors to exclude NHL patients from this pro-
edure. A more speciﬁc characterization of salvage
esponse, such as that used in this study, may more
ccurately reﬂect the prognosis of NHL patients un-
ergoing RIST and should be evaluated prospectively
n future studies.
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